Common questions about Glivec (FAQ)
Q: What is the difference between Glivec and generic imatinib?
Glivec is the brand name established internationally for the medicine. The active ingredient, which performs the therapeutic action, is called imatinib mesylate. Official documents define imatinib mesylate as the active substance found in the Glivec product.
Q: Are there different strengths of Glivec tablets available?
Yes, Glivec is available in different strengths of film-coated tablets. According to the official prescribing information, the medicine is available in 100 mg and 400 mg tablet strengths.
Q: What kind of stomach issues are associated with taking Glivec?
Official product information lists common gastrointestinal side effects such as nausea, vomiting, and diarrhea. Less common but serious adverse reactions have also been reported, including stomach bleeding (haemorrhage) or perforation of the gastrointestinal tract.
Q: Does Glivec interact with over-the-counter pain relievers like ibuprofen?
Glivec is a known inhibitor of certain liver enzymes, such as CYP2C9, which are responsible for processing other drugs. Because of this, Glivec may increase the blood levels of other medicines metabolized by these enzymes. The prescribing information describes the need for caution when used with certain drug classes.
Q: Does Glivec interact with common supplements like Vitamin D or multivitamins?
Official documentation highlights the importance of discussing supplements that affect the CYP3A4 enzyme system. For instance, the herbal product St. John's wort is strictly contraindicated because it significantly decreases the blood levels of Glivec.
Q: What are the specific risks associated with taking Glivec during pregnancy?
Based on regulatory data, Glivec can cause fetal harm if used during pregnancy. Reports in women have included instances of spontaneous abortions and congenital anomalies in infants. Due to these documented risks, the regulatory label specifies that effective contraception should be used during treatment and for a period afterward.
Q: Why are people sometimes concerned about fluid retention in the face or ankles?
Fluid retention, or oedema, is a very common side effect documented in official safety information. It frequently appears as swelling around the eyes (periorbital oedema) and can also cause swelling in the legs and ankles.
Q: What is the connection between Glivec and bleeding risk?
Glivec is associated with haematological toxicities, which are conditions affecting the blood, including a decrease in platelets (thrombocytopenia). This reduction in platelets can increase the risk of bleeding. Gastrointestinal haemorrhage is also listed as an uncommon adverse reaction in the official safety profile.
Q: Is Glivec related to drugs used for rheumatoid arthritis?
Glivec is classified as a Protein-Tyrosine Kinase Inhibitor (TKI). This is a class of targeted medicines that includes other therapies approved for the treatment of various conditions, including certain inflammatory diseases like rheumatoid arthritis.
Q: Is Glivec considered a first-line treatment for its main indication?
Glivec is approved for use in newly diagnosed adult and pediatric patients with chronic phase Philadelphia chromosome positive Chronic Myeloid Leukemia (Ph+ CML). This indicates its intended use in newly diagnosed populations.
Q: What is the scientific basis for Glivec’s targeted mechanism?
The targeted action of Glivec is based on its selective inhibition of specific faulty enzymes, such as the BCR-ABL fusion protein (in CML) and mutated c-KIT or PDGFR (in GIST). This inhibitory activity acts to dismantle the underlying molecular fault that drives the excessive cell growth.
Q: Why is the dosage sometimes different for children compared to adults?
Dosing for pediatric patients is calculated based on Body Surface Area ( mg/m^2), rather than a fixed standard dose. This is a common and established method used to determine the appropriate drug exposure for children.
Q: Does Glivec cause hair loss?
Yes, alopecia (hair loss) is listed in official product information as a common adverse reaction. It is one of the many effects documented in the drug's safety profile.
Q: Is Glivec safe for people with kidney disease?
Glivec should be used with caution in patients with existing kidney disease (renal impairment). The regulatory guidance states that close monitoring of renal function is advised during treatment, as the medicine's effects may be increased.
Q: Are there any common foods or drinks that interact with Glivec?
The official regulatory information explicitly advises that the consumption of grapefruit and grapefruit juice should be avoided during treatment. This is because these products can increase the blood levels of Glivec.
Q: Why is the drug used for certain types of gastrointestinal tumors?
Glivec is used for Gastrointestinal Stromal Tumors (GIST) because it targets and inhibits specific proteins, such as c-KIT (CD117), that are responsible for driving the growth of these tumors. This targeted approach aims to interrupt the signaling pathways that cause the cells to proliferate.
Q: Is Glivec used to treat anything other than cancer?
Yes, Glivec is approved for the treatment of certain non-cancerous diseases in adults. These indications include specific forms of Hypereosinophilic Syndrome (HES) and Chronic Eosinophilic Leukemia (CEL) that involve a fault in the PDGFR gene.
Q: What happens if Glivec treatment is stopped?
Regulatory studies and official information state that treatment with Glivec is generally continuous and long-term. Research is ongoing to better characterize the observation of outcomes for CML patients who discontinue therapy after achieving a deep response, and treatment decisions are made by healthcare professionals based on individual patient assessment.
Q: Do I need special monitoring while taking Glivec?
Yes, regular monitoring is described in regulatory guidance. This typically includes check-ups, regular blood tests (such as Complete Blood Count/CBC), weight checks, and monitoring of liver enzymes and kidney function throughout therapy.
Q: How often are blood tests usually needed when taking Glivec?
Official prescribing information states that a Complete Blood Count (CBC) is generally performed weekly during the first month of therapy. Testing is then done biweekly during the second month, and periodically thereafter.
Q: Is it true that Glivec can be used for hypereosinophilic syndrome?
Yes, Glivec is an approved treatment for adult patients with hypereosinophilic syndrome (HES) who have the FIP1L1-PDGFRalpha fusion kinase. This is a specific non-cancer indication documented in regulatory labeling.
Q: What is the risk of skin reactions while taking Glivec?
Skin reactions, including a rash, are a very common adverse reaction documented in the official safety profile. More serious, but rare, skin reactions such as Stevens-Johnson Syndrome have also been reported.
Q: What are the official restrictions for using Glivec in older patients?
While there are no absolute contraindications based on age alone, official safety notes specify that older adults may experience a higher incidence of oedema (fluid retention). Specific caution and monitoring are documented in regulatory guidance when the medicine is used in this population.
Q: Is there a chance that the body becomes resistant to Glivec over time?
Regulatory research has investigated mechanisms of resistance in CML cells. The development of resistance to tyrosine kinase inhibitors is a known factor that may affect the progression of the disease.
Q: Why are there warnings about thyroid function with Glivec?
Warnings about thyroid function are documented, specifically regarding the reporting of hypothyroidism (underactive thyroid) in certain patients. This concern is noted especially in those who have had a thyroidectomy and are receiving thyroid hormone replacement therapy.
Q: Are there any specific dietary restrictions required for people taking Glivec?
The official regulatory information only notes one specific food restriction: the avoidance of grapefruit and grapefruit juice, which can increase the blood levels of the drug. Glivec is also officially administered with a meal and a large glass of water, as described in the instructions for use.
Q: Are there specific side effects that require immediate medical attention?
Yes, specific symptoms of serious adverse reactions are noted as needing immediate medical attention. These include signs of severe liver problems (e.g., yellowing of the skin/eyes), unusual bleeding/bruising, severe abdominal pain, and rapid, unexpected weight gain (a sign of severe fluid retention).
Q: Does Glivec affect the ability to drive or use machines?
Glivec may cause side effects such as dizziness, blurred vision, or drowsiness. Patients are advised in the regulatory information to exercise caution when driving or operating machinery until they know how the medicine affects them.
Q: What are the known potential effects of Glivec on bone health?
Official safety data lists muscle and bone pain as a common side effect of Glivec. Additionally, growth retardation has been reported in children and pre-adolescents receiving treatment due to the medicine's effect on developing tissues.
